Enveric Biosciences, Inc.
ENVB
$5.32
$0.224.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.24% | 22.30% | -0.03% | -25.20% | -28.20% |
| Depreciation & Amortization | -40.47% | -28.20% | -15.50% | -2.86% | -1.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.91% | 10.31% | -2.40% | -33.58% | -41.44% |
| Operating Income | 8.91% | -10.31% | 2.40% | 33.58% | 41.44% |
| Income Before Tax | 8.30% | 1.09% | 5.95% | 38.19% | 44.59% |
| Income Tax Expenses | -- | -70.00% | -76.47% | -76.47% | -69.20% |
| Earnings from Continuing Operations | 8.38% | 1.26% | 6.15% | 38.27% | 44.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.38% | 1.26% | 6.15% | 38.27% | 44.63% |
| EBIT | 8.91% | -10.31% | 2.40% | 33.58% | 41.44% |
| EBITDA | 7.76% | -11.85% | 1.94% | 34.34% | 42.28% |
| EPS Basic | 83.12% | 79.82% | 80.78% | 86.25% | 82.57% |
| Normalized Basic EPS | 86.10% | 80.80% | 80.73% | 86.19% | 82.39% |
| EPS Diluted | 83.12% | 79.82% | 80.78% | 86.25% | 82.57% |
| Normalized Diluted EPS | 86.10% | 80.80% | 80.73% | 86.19% | 82.39% |
| Average Basic Shares Outstanding | 698.93% | 484.94% | 426.71% | 403.75% | 249.90% |
| Average Diluted Shares Outstanding | 698.93% | 484.94% | 426.71% | 403.75% | 249.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |